— Study 3 Achieves Additional 26% LDL-C Lowering on Background of Maximally Tolerated LDL-C Lowering Therapy in Patients Considered Statin Intolerant —
— Additional hsCRP Reduction of 25% —
— Cumulative Phase 2 / Phase 3 Demonstrates Broad Efficacy as well as Safety and Tolerability —
— Conference Call and Webcast on Wednesday, May 23, 2018, at 8:45 a.
Esperion Announces Third Pivotal Phase 3 Study of Bempedoic Acid Meets Primary Endpoint
Понравилась статья? Подпишитесь на канал, чтобы быть в курсе самых интересных материалов
Подписаться